echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Latest Medical News > Hengrui Medicine's SHR-1701 injection and bevacizumab injection were approved for clinical trials

    Hengrui Medicine's SHR-1701 injection and bevacizumab injection were approved for clinical trials

    • Last Update: 2021-09-12
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    On the 6th, Hengrui Medicine issued an announcement stating that its subsidiary Shengdia Biomedical received the approval of the State Food and Drug Administration to issue the "Drug Clinical Trial Approval Notice" for SHR-1701 injection and bevacizumab injection.


    SHR-1701 can promote the activation of effector T cells, and at the same time can effectively improve the immune regulation in the tumor microenvironment, and ultimately effectively promote the immune system to kill tumor cells


    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.